By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#112 – Ned David, Ph.D.: How cellular senescence influences aging, and what we can do about it
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:11 – 4:50
Setting the stage: Ned David, Unity Biotechnology, and why senescence matters
Peter Attia introduces Ned David and frames the episode around cellular senescence as a key mechanism within the broader biology of aging. He previews how the conversation will connect senescence to other longevity pathways and to Ned’s experience building biotech companies.
- •Peter outlines the show’s goal of translating longevity science into accessible insights
- •Ned is introduced as president and co-founder of Unity Biotechnology
- •The discussion is framed as senescence in context with other aging processes (e.g., mTOR, mitochondria, epigenetics)
- •Peter foreshadows lessons from Ned’s biotech entrepreneurship and drug development experience
- 4:50 – 7:07
What “longevity” means to Ned: escaping the indignities of aging
Ned defines longevity through lived experience—seeing immobility and dementia shape people’s lives. He describes longevity as using science to reduce the burdens of age-related decline, and notes that human data is beginning to support that idea.
- •Ned describes degenerative disc disease and Alzheimer’s as examples of age-related suffering
- •Longevity is framed as preserving function and dignity rather than simply extending years
- •Ned connects his motivation to applying biology and drug development to aging
- •He emphasizes the significance of generating human data, not just theory
- 7:07 – 10:39
Aging as malleable: three principles and the “control knobs” framework
Ned lays out three principles for thinking about aging: it’s flexible, nature alters it using biochemical “control knobs,” and those knobs can be targeted. He supports the idea with examples of huge lifespan differences across related species.
- •Aging is described as flexible rather than fixed
- •Nature modulates lifespan through biochemical control systems (“knobs”)
- •These knobs are potentially ‘turnable’ by drug development
- •Examples of lifespan variation across similar species (clams, mammals, rodents) illustrate malleability
- 10:39 – 14:56
Single-gene longevity and the IGF signaling story (DAF-2/DAF-16)
Ned recounts how a landmark worm experiment showed lifespan doubling by altering a single gene, changing the field’s assumptions about aging. Peter challenges the extrapolation to mammals, and Ned explains how the pathway translates imperfectly but still validates the “knobs” concept.
- •A single-gene manipulation in worms produced dramatic lifespan extension
- •Ned describes DAF-2/DAF-16 as part of IGF-1 receptor signaling biology
- •Peter notes mammalian effects are smaller than in worms
- •Ned stresses the core insight: aging can be shifted by manipulating discrete pathways
- 14:56 – 18:28
Caloric restriction, rapamycin, and mTOR: the most reproducible aging knob
Ned describes caloric restriction’s accidental discovery and its link to rapamycin and mTOR biology. He calls mTOR-related interventions the best-validated, cross-lab and cross-species mechanism, highlighting reproducibility as a hallmark of “real biology.”
- •Caloric restriction effects were first observed unintentionally in rodent experiments
- •Rapamycin’s aging relevance emerged later and linked to caloric restriction via mTOR
- •mTOR is framed as a master decision system for growth vs. survival
- •Reproducibility across labs and species is emphasized as a key validation criterion
- 18:28 – 23:02
Other aging knobs: young blood, mitochondria, and the methylation clock debate
The conversation surveys additional aging mechanisms: circulating factors from young animals, mitochondrial decline, and epigenetic “methylation clock” changes. Ned emphasizes uncertainties—especially whether methylation changes are cause, consequence, or both.
- •Parabiosis studies suggest factors in young circulation can benefit old animals
- •Mitochondrial DNA mutates much faster than nuclear DNA, contributing to dysfunction
- •Ned describes age-related loss of mitochondrial function in human colonic crypt cells
- •The methylation clock is presented as promising but unresolved in causality
- 23:02 – 27:22
Yamanaka factors and ‘factory reset’ caution: youth vs. cell fate reprogramming
Peter and Ned discuss epigenetic resetting at conception and during germ cell formation, and how Yamanaka factors can artificially induce reprogramming. Ned cautions against equating an embryonic-like state with “youth,” arguing reprogramming is fundamentally a cell fate shift.
- •Two natural ‘resets’ of the methylome are described: conception and germ-cell formation
- •Yamanaka factors can reprogram cells inefficiently into a reset state
- •Ned argues reprogramming creates a unique state that may share features with youth but isn’t identical to it
- •They discuss the need for experiments that test whether altering methylation makes cells functionally younger
- 27:22 – 31:44
Why senescence is Unity’s focus: the simplest mechanism to turn into medicine
Ned transitions from broad aging biology to cellular senescence as a practical drug target. He defines senescent cells as permanently growth-arrested cells that accumulate with age and describes key mouse experiments showing that clearing them improves health and extends lifespan.
- •Senescence is introduced as a key, druggable aging mechanism
- •Senescent cells arise when cells hit stress they can’t resolve and permanently stop dividing
- •These cells accumulate with age and are typically a small fraction of total cells
- •Genetic clearance of senescent cells in mice improves multiple aging features and extends average lifespan
- 31:44 – 40:37
Cancer, apoptosis vs. senescence, and the toxic secretome (SASP)
The discussion addresses why senescence exists and why targeting it might be safe: blocking the ability to become senescent increases tumors, but clearing already-senescent cells is different. Peter and Ned unpack the apoptosis-versus-senescence fork and explain SASP as the mechanism by which few cells can disrupt whole tissues.
- •Ned explains senescence as an essential anti-cancer ‘emergency brake’
- •Peter frames the apoptosis vs. senescence decision after irreparable damage
- •They note uncertainty about what determines whether a cell dies or becomes senescent
- •SASP is introduced as a paracrine secretome that drives inflammation, fibrosis, and tissue dysfunction
- 40:37 – 47:48
Senescence history: Hayflick’s discovery, biomarkers, and SASP evolution
Ned traces senescence from Hayflick overturning the idea of limitless cell division to later in vivo detection and mechanistic insight. He describes how biomarkers enabled counting senescent cells in tissues and how SASP discovery explained their outsized impact.
- •Hayflick identified a limit to cell division and coined senescence terminology
- •Historical lab limitations contributed to earlier misconceptions about infinite division
- •Judy Campisi identified an early in vivo biomarker enabling detection in tissues
- •SASP discovery in 2008 provided a mechanism for senescent-cell harm and showed tissue/context specificity
- 47:48 – 53:48
Why SASP exists at all: tradeoffs, wound healing, and aging as a side effect
Peter questions why SASP is so destructive, and Ned offers a framework: many aging features are beneficial earlier in life. Ned describes research showing senescent cells and SASP can aid wound healing, supporting the idea of beneficial functions that become harmful when persistent in aging tissues.
- •They discuss the limits of teleological explanations while acknowledging useful frameworks
- •Ned notes aging phenotypes often appear post-reproductively, reducing evolutionary ‘pressure’ to fix them
- •Senescent cells accumulate at wound sites and can facilitate wound closure
- •Persistent SASP signaling may represent a beneficial program that becomes pathological when it doesn’t shut off
- 53:48 – 59:07
The 2011 breakthrough and Unity’s founding: BubR1 mice and a drug-like idea
Ned recounts the moment he saw the key 2011 data and realized senescent-cell clearance ‘smelled like a drug.’ He explains the BubR1 model that unexpectedly caused rapid aging and how senescent cell elimination blunted multiple aging features, motivating company formation.
- •Ned describes receiving the 2011 paper and immediately recognizing translational potential
- •The BubR1 mutation caused rapid aging features and heavy senescent-cell burden rather than expected cancer
- •Eliminating senescent cells reduced several aging-like phenotypes even in a very sick model
- •Ned contacted Jan van Deursen quickly and began forming the company around the concept
- 59:07 – 1:16:11
Stealth-mode de-risking: the four questions that determined whether Unity could exist
Ned describes four foundational questions Unity pursued under tight constraints: relevance to natural aging, a treatable human disease target, existence of drug-like senolytics, and safety. He details how these questions guided budgets, experiments, and go/no-go decisions over several years.
- •Four risks: relevance to natural aging, disease applicability, drug discovery feasibility, and safety
- •They pursued the work with limited resources and a highly focused plan
- •Natural-aging validation required long experiments culminating in a 2016 publication
- •Ned explains how risk framing shaped company-building and experimental priorities
- 1:16:11 – 1:19:27
Choosing senolytics over SASP suppression: why killing cells could be safer long-term
Ned explains Unity’s strategic decision to prioritize eliminating senescent cells rather than only suppressing SASP. The key advantage is intermittent dosing—removing the source of harmful factors rather than continuously blocking downstream effects.
- •Two strategies were considered: remove senescent cells or suppress the SASP program
- •Suppressing SASP would likely require chronic dosing and assumes control of a complex factor network
- •Senolytics offer the possibility of infrequent dosing because cleared cells are gone
- •Ned previews clinical observations suggesting durable benefit after a single administration
- 1:19:27 – 1:45:10
Osteoarthritis: from animal models to human trials, pain reduction, and what’s next
Ned details how Unity linked senescence to osteoarthritis using trauma models and human tissue experiments, then translated that into a clinical program. He describes a single-injection phase 1 study showing dose-dependent, durable pain reduction, and explains how phase 2 aims to validate effects and assess structural changes via imaging.
- •Trauma-induced osteoarthritis models showed senescent-cell clearance reduced pain and supported cartilage repair in mice
- •Human knee tissue experiments showed drug exposure reduced senescent cells and enabled cartilage production in culture
- •Phase 1: single intra-articular injection, dose escalation, double-blind, with pain tracked frequently
- •Phase 2 expands duration and sample size and includes imaging to assess joint structure alongside pain outcomes
- 1:45:10
Beyond joints: atherosclerosis, oncology hypotheses, eye disease programs, and brain aging
The conversation broadens to other age-related diseases where senescence may matter, including atherosclerosis, cancer timing, macular degeneration, and neurodegeneration. Ned describes why local diseases were a starting point, outlines planned eye trials with different drug targets, and shares ongoing interest in glial senescence and cognition.
- •Atherosclerosis: senescent cells in plaques and potential effects on plaque volume and fibrotic cap thickness in mouse models
- •Cancer: mice still die largely of the same cancers but later, suggesting delayed onset rather than reduced prevalence
- •Eye diseases: planned intravitreal delivery; new molecules target BCL2 family and show disease-state selectivity in animals
- •Brain: senescent astrocytes and microglia increase with age; the company is investigating implications for cognition and Alzheimer’s-related decline
Entrepreneurship lessons and career guidance: risks, mentorship, and avoiding false choices
Peter shifts to Ned’s entrepreneurial process and career advice. Ned emphasizes reverse-engineering success by identifying failure modes, using portfolio thinking, learning from experienced partners, and not treating academia vs. industry as a forced binary choice.
- •Ned describes a method: envision the end state, list existential risks, and build de-risking plans
- •He reflects on learning discipline through earlier companies and mistakes
- •He encourages academics to be explicit about failure modes and to make formal go/no-go decisions
- •Career advice: avoid false choices, pursue a motivating ‘beautiful idea,’ and learn from mentors with experience
